Literature DB >> 11699047

Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.

D Kramer1, R Shapiro, A Adler, E Bush, C M Rondinone.   

Abstract

Thiazolidinediones (TZDs), a class of antidiabetic agents, are specific agonists of peroxisome proliferator activator receptor (PPARgamma). However, their mechanisms of action, and the in vivo target tissues that mediate insulin sensitization are not well understood. The aim of this study was to investigate the role of glucose transporters (GLUT-1 and GLUT-4) in the TZD insulin-sensitizer action. The effects of rosiglitazone treatment were studied using Zucker (fa/fa) rats after 7 days of oral dosing (3.6 mg/kg/d). Rosiglitazone lowered (approximate 80%) basal plasma insulin levels in obese rats and substantially corrected (approximately 50%) insulin resistance based upon results from hyperinsulinemic euglycemic clamp studies. GLUT-4 protein levels were reduced (approximately 75%) in adipose tissue of obese rats and treatment with rosiglitazone normalized them. Interestingly, GLUT-1 protein content was increased in adipose tissue ( thick approximate 150%) and skeletal muscle (approximately 50%) of obese rats and treatment with rosiglitazone increased it even more by 5.5-fold in fat and by 2.5-fold in muscle. Consistent with these results, basal (GLUT-1-mediated) transport rate of 3-O-methyl-D-glucose into isolated epitrochlearis muscle was elevated in response to rosiglitazone. Incubation of fully differentiated 3T3-L1 adipocytes with the drug for 7 days increased the levels of GLUT-1 protein, but did not affect GLUT-4 levels. In conclusion, rosiglitazone may improve insulin resistance in vivo by normalizing GLUT-4 protein content in adipose tissue and increasing GLUT-1 in skeletal muscle and fat. While the drug has a direct effect on GLUT-1 protein expression in vitro without a direct effect on GLUT-4 suggests that direct and indirect effects of rosiglitazone on glucose transporters may have an important role in improving insulin resistance in vivo. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699047     DOI: 10.1053/meta.2001.27202

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  29 in total

1.  Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.

Authors:  Daozhong Jin; Hong Guo; So Young Bu; Yuanyuan Zhang; Jennifer Hannaford; Douglas G Mashek; Xiaoli Chen
Journal:  FASEB J       Date:  2010-10-25       Impact factor: 5.191

2.  Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.

Authors:  Yun Li; Qiong-hong Xie; Huai-zhou You; Jing Tian; Chuan-ming Hao; Shan-yan Lin; Tong-ying Zhu
Journal:  Perit Dial Int       Date:  2012-03-01       Impact factor: 1.756

3.  Deficiency of FcϵR1 Increases Body Weight Gain but Improves Glucose Tolerance in Diet-Induced Obese Mice.

Authors:  Yun-Jung Lee; Conglin Liu; Mengyang Liao; Galina K Sukhova; Jun Shirakawa; Meriem Abdennour; Karine Iamarene; Sebastien Andre; Karen Inouye; Karine Clement; Rohit N Kulkarni; Alexander S Banks; Peter Libby; Guo-Ping Shi
Journal:  Endocrinology       Date:  2015-08-21       Impact factor: 4.736

Review 4.  Antidiabetic plant-derived nutraceuticals: a critical review.

Authors:  Jayapal Naveen; Vallikannan Baskaran
Journal:  Eur J Nutr       Date:  2017-10-11       Impact factor: 5.614

5.  Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes.

Authors:  Pooja Pal; Jitendra K Kanaujiya; Savita Lochab; Shashi B Tripathi; Sabyasachi Sanyal; Gerhard Behre; Arun K Trivedi
Journal:  Mol Cell Biochem       Date:  2012-12-30       Impact factor: 3.396

6.  Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.

Authors:  H Kim; M Haluzik; O Gavrilova; S Yakar; J Portas; H Sun; U B Pajvani; P E Scherer; D LeRoith
Journal:  Diabetologia       Date:  2004-12-15       Impact factor: 10.122

Review 7.  Nonischemic heart failure in diabetes mellitus.

Authors:  Ashrith Guha; Romain Harmancey; Heinrich Taegtmeyer
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

8.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

9.  Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.

Authors:  Rai Ajit K Srivastava; Ravi Jahagirdar; Salman Azhar; Somesh Sharma; Charles L Bisgaier
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

10.  Rosiglitazone modulates insulin-induced plasma membrane area changes in single 3T3-L1 adipocytes.

Authors:  Jelena Velebit; Petra Brina Kovacic; Mateja Prebil; Helena H Chowdhury; Sonja Grilc; Marko Kreft; Jørgen Jensen; Esma R Isenović; Robert Zorec
Journal:  J Membr Biol       Date:  2008-08-27       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.